Zongertinib

CAS No. 2728667-27-2

Zongertinib( —— )

Catalog No. M36284 CAS No. 2728667-27-2

Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 225 Get Quote
5MG 353 Get Quote
10MG 471 Get Quote
25MG 685 Get Quote
50MG 891 Get Quote
100MG 1107 Get Quote
200MG 1503 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Zongertinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD).
  • Description
    Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    HER/HSP
  • Recptor
    HER | Tyrosine Kinases
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2728667-27-2
  • Formula Weight
    535.6
  • Molecular Formula
    C29H29N9O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 31.25 mg/mL (58.35 mM; Ultrasonic (<60°C)
  • SMILES
    N(C=1C2=C(C=NC(=N2)N3CCC(NC(C=C)=O)CC3)N=CN1)C4=CC(C)=C(OC=5C=C6C(=CC5)N(C)C=N6)C=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. WHO Drug Informat ion - World Health Organization (WHO).
molnova catalog
related products
  • DZD9008

    DZD9008 is a rationally designed selective, irreversible EGFR/HER2 inhibitor.

  • PF-04929113

    PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.

  • Ginsenoside Rg3

    Ginsenoside Rg3 possess an ability to inhibit the lung metastasis of tumor cells via inhibition of the adhesion and invasion of tumor cells.